DAIICHI SANKYO UK LIMITED

1. DAIICHI SANKYO UK LIMITED 2006-05-17 → present
2. SANKYO PHARMA UK LIMITED 1997-04-02 → 2006-05-17
3. PANPHARMA LIMITED 1986-05-16 → 1997-04-02
4. GAGETREK LIMITED 1986-03-12 → 1986-05-16

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements are prepared on a going concern basis which the directors believe to be appropriate for the following reasons. The Company has strong balance sheet position, with a cash balance of £13.38m (2024: £38.28m) and net assets of £15.29m as at 31 March 2025 (2024: £16.26m), having made a profit after tax for the year of £9.58m (2024: £8.46m). The directors continue to consider the significant geo-political challenges currently facing the world, as well as the recent cost of living crisis and the UK Government's actions to maintain its fiscal strategies and how they potentially impact on the entity's operations. They are also very aware of the on-going risks relating to the patent lifecycle of their own products and those of their direct competition. To date these challenges have not significantly impacted the Company's operations or demand for the Company's products. The Directors have prepared cashflow forecasts to support their assessment of a 12 month look forward period, including a severe but plausible downside scenario that could arise if revenues were to reduce compared to the board's current expectations. In preparing those forecasts they have considered two key risks occurring simultaneously, firstly a significantly reduced growth profile of their 3 main recent launch brands, and secondly a sharper reduction in its key atrial fibrillation product as a result of a potential generic entrance impacting two of the key competitors in this category. The revenue reduction modelling is accompanied by appropriate corresponding inventory purchase cost reductions which are considered realistic based on the implied revenue reduction, as well as a realistic reduction in operating expenses due to the expected removal of revenue growth. Accordingly, the directors are confident that the Company will have sufficient funds to continue in operational existence and to meet its liabilities as they fall due for at least 12 months from the date of approval of these financial statements. Therefore, they continue to adopt the going concern basis of accounting in preparing these financial statements.”

Significant events

• “The company made charitable donations of £163,497 during the year (2024: £61,076).”
• “On 17 June 2025 the trustees of the Company's defined benefit pension scheme entered into a buy-in agreement with an insurance provider. The transaction occurred after the reporting period and does not provide evidence of conditions that existed at the balance sheet date. Accordingly, it is classified as a non-adjusting post balance sheet event under IAS 10 Events After the Reporting Period, and no adjustment has been made to the financial statements as at 31 March 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +41.6%

  £147,940,000 → £209,490,000

• Cash

  -65%

  £38,281,000 → £13,383,000

• Net assets

  -6%

  £16,262,000 → £15,293,000

• Employees

  +6.1%

  197 → 209

• Operating profit

  +13.4%

  £9,428,000 → £10,687,000

• Profit before tax

  +8.6%

  £11,369,000 → £12,344,000

• Wages

  +16.2%

  £17,227,000 → £20,015,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers